Anzeige
Meldung des Tages: Die Almonty-Verbindung: Kanadas vergessene Wolfram-Entdeckung mit Sangdong-Potenzial?

Sanofi

Aktie
WKN:  920657 ISIN:  FR0000120578 US-Symbol:  SNYNF Branche:  Medikamente Land:  Frankreich
71,73 €
+0,55 €
+0,77%
08:47:55 Uhr
Depot/Watchlist
Marktkapitalisierung *
85,69 Mrd. €
Streubesitz
47,22%
KGV
8,32
Dividende
3,92 EUR
Dividendenrendite
5,29%
Nachhaltigkeits-Score
69 %
Index-Zuordnung
Euro Stoxx 50
Weiter aufwärts? Long handeln - Jetzt mit Faktor 2,00: UL7XYY
Werbung

Ad-hocs

15.12.25 - GlobeNewswire
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
15.12.25 - GlobeNewswire
Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
Sanofi provides update on tolebrutinib regulatory submission in non-​relapsing secondary progressive multiple sclerosis
11.12.25 - GlobeNewswire
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-​lowering therapy for hemophilia, can offer consistent protection with as ...
04.12.25 - GlobeNewswire
Press Release: Sanofi completes acquisition of Vicebio
Sanofi completes acquisition of Vicebio
25.11.25 - GlobeNewswire
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing ...
14.11.25 - GlobeNewswire
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
07.11.25 - GlobeNewswire
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for ...
28.10.25 - GlobeNewswire
Press release: Sanofi successfully prices USD 3 billion of bond issue
Sanofi successfully prices USD 3 billion of bond issue
24.10.25 - GlobeNewswire
Press release: Q3: continued sales and earnings progress
22.10.25 - GlobeNewswire
Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-...
20.10.25 - GlobeNewswire
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program If approved, Tzield would be ...
20.10.25 - GlobeNewswire
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-​dose
17.10.25 - GlobeNewswire
Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
17.10.25 - GlobeNewswire
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-​vs-host disease

Newssuche

Videos

newspaper
14.10.26 -18,73%
Technical Trading: 88,9% Trefferquote
Rohöl Short Typ: Turbo Open End WKN: BD78MJ Hebel: 30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Weitere Videos ❯

Weitere Vorteile:

  • Kursalarme
  • Watchlists & Musterdepots
  • Börsenspiele & Community-Forum
  • Historische Kurse im CSV-Format
  • News & Themen abonnieren

Jetzt abstimmen und gewinnen!

Auch in diesem Jahr nimmt ARIVA.DE wieder an den Zertifikate Awards teil. Stimme jetzt für deine Favoriten ab - deine Stimme zählt!

✈️
Zu gewinnen
Eine Reise nach Berlin

Jetzt abstimmen →